CMS releases revised guidance for Medicare drug price negotiation program
On June 30, CMS published Revised Guidance regarding the Medicare Drug Price Negotiation Program in which CMS will negotiate with drug manufacturers to set maximum fair prices for certain high-expenditure, single-source drugs without generic or biosimilar alternatives.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.